McLane freshens up in-store offerings
Consumables have long been a major component of any drug store’s product mix, but where stores historically have limited their offerings to soft drinks, candy and beer, more of them now are selling fresh produce and prepared foods.
Temple, Texas-based supply chain services provider McLane is one company that can help retail pharmacies freshen up their inventories. McLane operates a network of 19 facilities that allow the company to reach every ZIP code in the continental United States with its 2,000 temperature-controlled trailers delivering everything from frozen food to fresh vegetables and fruits.
“Through that network of providing multitemp options or just a large dynamic of items, we have the ability to tailor or customize a product mix,” McLane category manager for perishable, supplies and food service Greg Tradup told Drug Store News. “Anything you could find in a grocery store, we have the ability to tailor for a drug store.”
Tradup sees retail pharmacies as well-positioned to address the food desert problem. “I think a pharmacy, being a little bit more local, has probably the most unique ability to offer up a fresh food program where it might not be available locally,” he said. But retailers have to do it right to be successful.
This includes placing fresh foods in areas where customers will notice them, such as open-air coolers near the front of the store.
“There needs to be more involvement from the operators and the workers there in the store in regard to maintaining the programs, rotating the items and keeping the areas clean,” Tradup said. “They definitely need to advertise, make it known these items are available [and] put them in an area where they’re recognizable and can be seen.”
Sagent gets OK for antibacterial drug
SCHAUMBURG, Ill. — Sagent has received approval from the Food and Drug Administration for its antibacterial drug.
The drug maker said that the FDA approved polymyxin B for injection USP. Sagent said that polymyxin B sulfate is used to treat infections of the urinary tract, meninges and bloodstream caused by susceptible strains of Pseudomonas aeruginosa.
The drug was developed in partnership with Strides Arcolab. Under the collaboration, Strides develops and supplies injectable products that Sagent will market in the United States.
Shire files suit against Amneal, Sandoz over generic Vyvanse
DUBLIN — Shire has filed patent infringement suits against two generic drug makers relating to its attention deficit hyperactivity disorder treatment.
Shire said it has filed lawsuits in the U.S. District Court for the District of New Jersey against Amneal Pharmaceuticals and Sandoz. Amneal and Sandoz recently filed abbreviated new drug applications with the Food and Drug Administration to market generic Vyvanse (lisdexamfetamine), an ADHD drug.
Citing the Hatch-Waxman Act, Shire said that the FDA mustn’t approve the ANDAs for generic Vyvanse until the patents expire on Aug. 23, 2014, or until a district court decision finding that the patents are invalid or not infringed, whichever occurs earlier.